We met with Dr Jeff Cummings, from the US Neurology Editorial Board, to discuss the current treatment landscape in Alzheimer’s disease, and recent clinical trials for new drugs.
Speaker disclosures: In kind research support from Avid Radiopharmaceuticals, Teva Pharmaceuticals, and CogState. Dr Cummings has provided consultation to Abbvie, Acadia; Accera, Actinogen, ADAMAS, Alkahest, Alzheon, Anavex, Astellas, Astra Zeneca, Avanir, Axovant, Biogen-Idec, Biotie, Boehinger-Ingelheim, Chase, Eisai, Forum, Genentech, Grifols, Intracellular Therapies, IRIS, Ionis Pharmaceuticals, Lilly, Lundbeck, Merck, Neurotrope, Novartis, Nutricia, Otsuka, Pfizer, Probiodrug, QR Pharma, Resverlogix, Roche, Servier, Sunovion, Suven, Takeda, Toyoma, Transition Therapeutics, and United Neuroscience, companies. Dr Cummings has provided consultation to GE Healthcare and MedAvante. Dr Cummings owns stock in ADAMAS, Prana, Sonexa, MedAvante, Neurotrax, and Neurokos. Dr Cummings owns the copyright of the Neuropsychiatric Inventory. Dr Cummings has provided expert witness consultation regarding olanzapine and ropinerol.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Boston, US, April 2017
